Clinical Trial Update: EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Tulmimetostat, an EZH2 inhibitor, in combination with a PD-1 blockade for advanced non-small cell lung cancer; currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PD-1 inhibitor
• Tulmimetostat (Tulmimetostat)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING